Article metrics

Download PDFPDF

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis

 

Online download statistics by month:

Online download statistics by month: September 2020 to April 2024

AbstractFullPdf
Sep 202011131090288
Oct 202011101095528
Nov 2020774769229
Dec 2020481469182
Jan 2021322313146
Feb 202124023597
Mar 2021310303106
Apr 202118918674
May 202117617458
Jun 202119919669
Jul 202115815351
Aug 202120019374
Sep 202116916862
Oct 202116916482
Nov 202118718178
Dec 202113613462
Jan 202214814353
Feb 202210910948
Mar 202217918069
Apr 202215215142
May 202215215357
Jun 202215315429
Jul 202211410734
Aug 202212212226
Sep 202215014284
Oct 202210310244
Nov 202213112740
Dec 2022696523
Jan 202311010329
Feb 202314113941
Mar 202313313039
Apr 202311010640
May 202314114153
Jun 202311811330
Jul 202315615451
Aug 202311110827
Sep 202311711626
Oct 202313813244
Nov 202313913336
Dec 202311510834
Jan 2024746122
Feb 20241129029
Mar 202413913648
Apr 202411710849
Total948692563333